26 citations
,
October 2016 in “American journal of clinical dermatology” New treatments like JAK inhibitors show promise for reversing alopecia areata.
6 citations
,
February 2023 in “International Journal of Women’s Dermatology” Patients with alopecia areata face high costs for wigs due to poor insurance coverage.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
5 citations
,
July 2020 in “Recent patents on inflammation & allergy drug discovery” Childhood Alopecia Areata causes hair loss and requires varied treatments, with psychological support being crucial.
4 citations
,
November 2025 in “Nature Reviews Disease Primers” September 2022 in “Journal of Sulaimani Medical College” The combination treatment showed some improvement but wasn't significantly better than using betamethasone valerate alone.
70 citations
,
August 2019 in “European Journal of Medicinal Chemistry” 23 citations
,
March 2017 in “JAAD case reports” The document suggests a possible link between FAM111B gene mutations and increased cancer risk, particularly pancreatic cancer.
17 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
15 citations
,
January 2015 in “Dermatitis” Topical immunotherapy is the best treatment for severe alopecia areata.
14 citations
,
April 2017 in “Dermatology practical & conceptual” Yellow dots are common in severe alopecia areata.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
12 citations
,
May 2015 in “Journal of the National Comprehensive Cancer Network” Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.
2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
2 citations
,
June 2024 in “Journal of Clinical Medicine” Alopecia Areata can affect nails, often improving on its own, but JAK inhibitors may help.
1 citations
,
August 2025 in “Medicina” Non-invasive imaging techniques improve scalp condition diagnosis and patient quality of life.
1 citations
,
November 2024 in “JAAD reviews.” Patients with alopecia areata prefer effective, safe, and convenient treatments, especially topical ones.
1 citations
,
January 2024 in “Updates in clinical dermatology”
1 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
February 2026 in “Dove Medical Press (Taylor and Francis Group)” Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
January 2026 in “British Journal of Health Psychology” Alopecia affects self-confidence, body image, and social interactions, causing distress and requiring better support and awareness.
January 2026 in “Case Reports in Dermatological Medicine” Lichen Planus in siblings may be influenced by genetics and environment.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
October 2025 in “Dermatologica Sinica” A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.
August 2025 in “Frontiers in Immunology” Primary cicatricial alopecia is linked to various health issues, indicating broader systemic problems.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
December 2023 in “Journal of dermatology” Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.